We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

63 hedge funds and large institutions have $80.7M invested in LENZ Therapeutics in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

0% more funds holding

Funds holding: 63 → 63 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.52% less ownership

Funds ownership: 8.96% → 7.44% (-1.5%)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

57% less capital invested

Capital invested by funds: $186M → $80.7M (-$105M)

72% less call options, than puts

Call options by funds: $59K | Put options by funds: $210K

Holders
63
Holders Change
–
Holders Change %
0%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
11
Reduced
14
Closed
28
Calls
$59K
Puts
$210K
Net Calls
-$151K
Net Calls Change
-$151K

Top Buyers

1
TCM
Tang Capital Management
California
+$3.5M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.51M
3
LCM
Laurion Capital Management
New York
+$1.83M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.39M
5
Millennium Management
Millennium Management
New York
+$1.28M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$13.8M
2
RSCM
Rock Springs Capital Management
Maryland
-$9.13M
3
VA
VR Adviser
New York
-$8.22M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.41M
5
BlackRock
BlackRock
New York
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$23.3M +$1.23M +55,244 +5%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$14.4M -$6.41M -287,571 -28%
Citadel Advisors
3
Citadel Advisors
Florida
$3.63M +$207K +9,306 +5%
EC
4
EcoR1 Capital
California
$3.2M +$439K +19,700 +13%
TCM
5
Tang Capital Management
California
$3.02M +$3.5M +157,143 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.93M -$442K -19,835 -12%
Federated Hermes
7
Federated Hermes
Pennsylvania
$2.9M – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$2.17M +$2.51M +112,471 New
Morgan Stanley
9
Morgan Stanley
New York
$1.98M +$503K +22,545 +28%
APM
10
Avidity Partners Management
Texas
$1.95M – – –
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$1.93M – – –
AG
12
Artal Group
Luxembourg
$1.93M – – –
LCM
13
Laurion Capital Management
New York
$1.58M +$1.83M +81,943 New
Millennium Management
14
Millennium Management
New York
$1.45M +$1.28M +57,495 +325%
BlackRock
15
BlackRock
New York
$1.34M -$3.84M -172,357 -71%
OM
16
Opaleye Management
Massachusetts
$1.26M +$651K +29,214 +80%
Two Sigma Investments
17
Two Sigma Investments
New York
$1.2M +$1.39M +62,466 New
Goldman Sachs
18
Goldman Sachs
New York
$1.15M +$1.21M +54,399 +1,021%
OMC
19
OUP Management Company
Pennsylvania
$1.12M – – –
KPF
20
K2 Principal Fund
Ontario, Canada
$1.1M +$1.28M +57,382 New
PFMU
21
Privium Fund Management (UK)
United Kingdom
$948K +$1.1M +49,224 New
WP
22
Woodline Partners
California
$825K – – –
OMC
23
Oasis Management Company
Cayman Islands
$702K +$812K +36,443 New
Two Sigma Advisers
24
Two Sigma Advisers
New York
$659K +$763K +34,243 New
CAM
25
Cormorant Asset Management
Massachusetts
$549K -$11.5K -515 -2%
1
2 3 4

LENZ Hedge Fund Activity: Q2 2022 in Review

63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2022, worth a combined $80.7M — down 57% from $186M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LENZ positions and 28 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $3.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.8M sold.

  • 63 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $80.7M of LENZ Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
  • 29 funds opened new LENZ Therapeutics positions in Q2 2022 and 28 closed out, a net change of +1 holder.
  • The largest LENZ Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $3.5M added.
  • The largest LENZ Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q2 2022.